PriceSensitive

ResApp Health (ASX:RAP) partners with Medgate for telehealth pilot

Health Care
ASX:RAP
09 November 2020 11:00 (AEDT)
ResApp Health (ASX:RAP) - Managing Director & CEO, Dr Tony Keating

Source: ResApp Health

ResApp Health (RAP) has signed an agreement to run its smartphone-based
acute respiratory diagnostic test in Medgate AG’s telemedicine services.

Medgate is a leading provider of digital health in Europe and also runs the region’s largest telemedical centre in Switzerland, with 500 employees.

The joint development and pilot agreement between the digital health company and Medgate will last for six months.

For the first two months of the agreement, the companies will focus on building RAP’s ResAppDx into Medgate’s services.

From there, a three-month pilot will be carried out, testing the integration of the two programs.

The pilot is expected to begin in early 2021, with both Medgate and ResApp to jointly assess its success on a number of key indicators.

Commenting on the pilot, RAP CEO and Managing Director Tony Keating said he was very pleased to have entered into this agreement.

“Medgate is a well-known and respected organisation and we look forward to working with them to deliver our ResAppDx product to their customers,” he said.

“This partnership is ongoing validation of our offering and will potentially allow the company to pursue a large market opportunity in Europe, as well as in Asia and the Middle East where Medgate also has operations,” he added.

ResApp won’t be paid for participating in the pilot, but both parties are expected to enter into negotiations on a future cost model.

Shares in RAP are trading up 9.3 per cent for 9.4 cents each at 11:14 am AEDT.

Related News